Study Characteristic | N (%) |
---|---|
Continent of corresponding author | Â |
Africa | 11 (3.7) |
Asia | 58 (19.3) |
Australia | 16 (5.3) |
Europe (excluding UK) | 91 (30.3) |
North America | 87 (29.0) |
South America | 7 (2.3) |
United Kingdom | 30 (10.0) |
Type of journal | Â |
General medical journal | 19 (6.3) |
Specialty medical journal | 166 (55.3) |
General pediatric journal | 45 (15.0) |
Specialty pediatric journal | 70 (23.3) |
Study design | Â |
RCT parallel | 269 (89.7) |
RCT crossover | 19 (6.3) |
RCT factorial | 5 (1.7) |
Other | 7 (2.3) |
Study type | Â |
Efficacy/Superiority | 248 (82.7) |
Equivalence | 9 (3.0) |
Non-inferiority | 13 (4.3) |
Not declared | 2 (0.7) |
None of the above | 25 (8.3) |
Unclear | 3 (1.0) |
Nature of intervention | Â |
Drug | 121 (40.3) |
Vaccine | 16 (5.3) |
Natural health product | 26 (8.7) |
Device | 44 (14.7) |
Other | 93 (31.0) |
Placebo-controlled | 90 (30.0) |
Number of centres | Â |
Multicentre | 105 (35.0) |
Single Centre | 179 (59.7) |
Unclear | 16 (5.3) |
Sample size | Â |
Mean (SD) | 785.2 (5837.3) |
Median (range), IQR | 83 (6 - 71,799), 10 - 7079 |
Data Monitoring Committee established | 14 (4.7) |
Any adverse events reported | 129 (43.0) |
Funding source | Â |
Declared | 194 (64.7) |
Industry Sponsored | 67/194 (34.5) |
Primary outcome explicitly reported | 123 (41.0) |
At least one statistically significant outcome | 230 (76.7) |
Intervention favored | Â |
Treatment | 189 (63.0) |
Control | 19 (6.3) |
Neither | 92 (30.7) |
Common primary diagnostic categories | Â |
Acute Respiratory Infections | 17 (5.7) |
Airways | 14 (4.7) |
Anaesthesia | 18 (6.0) |
Developmental, Psychosocial, and Learning Problems | 20 (6.7) |
Ear, Nose, and Throat Disorders | 10 (3.3) |
Infectious Disease | 19 (6.3) |
Metabolic and Endocrine Disorders | 15 (5.0) |
Neonatal | 28 (9.3) |
Oral Health | 23 (7.7) |
Public Health | 16 (5.3) |